MAM
ONC

Myriad Asset Management’s BeOne Medicines Ltd ONC Stock Holding History

Myriad Asset Management’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-5,000
Closed -$828K – 111
2019
Q4 		$828K Buy
+5,000
New +$831K 0.1% 78

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
CII
Capital International Inc Los Angeles, California $14.3B AUM 34.19% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Myriad Asset Management's ONC Position: Q4 2019 in Review

Myriad Asset Management sold out of BeOne Medicines Ltd (ONC) in Q4 2019, closing a stake of 723,373 shares — an estimated $120M sold.

Myriad Asset Management first reported a position in ONC in Q1 2017 and held it in 7 quarters. The position peaked at $88.6M in Q3 2019. 221 funds tracked by Wall St. Rank hold ONC as of Q4 2019.

  • Myriad Asset Management reported no remaining BeOne Medicines Ltd position as of Q4 2019 after selling out during the quarter.
  • Myriad Asset Management sold 723,373 BeOne Medicines Ltd shares in Q4 2019, an estimated $120M.
  • Myriad Asset Management first reported a position in BeOne Medicines Ltd in Q1 2017 and held it in 7 quarters.
  • Myriad Asset Management's BeOne Medicines Ltd position peaked at $88.6M in Q3 2019.
  • 221 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q4 2019.

Based on Myriad Asset Management's 13F filing for Q4 2019, filed 11 Feb 2020.